» Articles » PMID: 27980581

Developing a CoMSIA Model for Inhibition of COX-2 by Resveratrol Derivatives

Overview
Publisher Brieflands
Specialty Pharmacology
Date 2016 Dec 17
PMID 27980581
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Design of selective cyclooxygenase-2 (COX-2) inhibitors is still a challenging task because of active site similarities between COX isoenzymes. To help with this issue, we tried to generate a 3D-QSAR (3 dimensional quantitative structure activity relationships) model that might reflect the essential features of COX-2 active sites. Compounds in a series of resveratrol derivatives inhibitors with reported biological activity against COX-2 were used to construct a predictive comparative molecular similarity indices (CoMSIA) model. A CoMSIA model with acceptable internal and external predictability was developed and employed to design new not yet synthesized molecules with improved activity and selectivity toward COX-2. Finally, molecular docking of the inhibitors in COX-2 active site demonstrated the possible ability of proposed compounds to inhibit COX-2, selectively.

Citing Articles

Resveratrol ameliorates oxaliplatin-induced neuropathic pain via anti-inflammatory effects in rats.

Dong Z, Wang Y, Wan W, Wu J, Wang B, Zhu H Exp Ther Med. 2022; 24(3):586.

PMID: 35949346 PMC: 9353538. DOI: 10.3892/etm.2022.11523.


Downregulation of mitochondrial cyclooxygenase-2 inhibits the stemness of nasopharyngeal carcinoma by decreasing the activity of dynamin-related protein 1.

Zhou T, Zhang S, He C, Zhuang Q, Han P, Jiang S Theranostics. 2017; 7(5):1389-1406.

PMID: 28435473 PMC: 5399601. DOI: 10.7150/thno.17647.

References
1.
Zarghi A, Arfaei S . Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships. Iran J Pharm Res. 2013; 10(4):655-83. PMC: 3813081. View

2.
Kurumbail R, Stevens A, Gierse J, McDonald J, Stegeman R, Pak J . Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996; 384(6610):644-8. DOI: 10.1038/384644a0. View

3.
Zarghi A, Sabakhi I, Topuzyan V, Hajimahdi Z, Daraie B . Design, synthesis and biological evaluation of 5-oxo-1,4,5,6,7,8 hexahydroquinoline derivatives as selective cyclooxygenase-2 inhibitors. Iran J Pharm Res. 2014; 13(Suppl):61-9. PMC: 3977054. View

4.
Limongelli V, Bonomi M, Marinelli L, Gervasio F, Cavalli A, Novellino E . Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition. Proc Natl Acad Sci U S A. 2010; 107(12):5411-6. PMC: 2851773. DOI: 10.1073/pnas.0913377107. View

5.
Chakraborti A, Garg S, Kumar R, Motiwala H, Jadhavar P . Progress in COX-2 inhibitors: a journey so far. Curr Med Chem. 2010; 17(15):1563-93. DOI: 10.2174/092986710790979980. View